PHV01 / Public Health Vaccines - LARVOL DELTA

PHV01-C-101: Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Public Health Vaccines LLC | Recruiting ➔ Completed | Trial primary completion date: Apr 2024 ➔ Sep 2024

Trial completion • Trial primary completion date • Infectious Disease

Study to Evaluate the Recombinant Vesicular Stomatitis Virus (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Public Health Vaccines LLC

New P1 trial • Infectious Disease

A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease. (PubMed, Vaccines (Basel)) - "Not only does this study highlight the potential predictive value of the guinea pig model in the evaluation of MARV countermeasures, but it also demonstrates consistent and reproducible protection afforded by a clonal vaccine candidate. Indeed, this study identifies PHV01 as a suitable vaccine candidate for advanced development."

Journal • Hematological Disorders • Infectious Disease